₩36,600.00 ($27.21)

-1400.00 (-3.68%)

Weekly Expected Move ±6.8%

₩31587 ₩34093 ₩36600 ₩39107 ₩41613

KOE · Healthcare · Medical - Pharmaceuticals · Tech Score Buy · Power 59 · ₩1.40T mcap · 31M float · 0.727% daily turnover

Revenue

$99.8B +193.6% ▲

5Y CAGR: +18.1%

Gross Profit

$96.5B +203.7% ▲

5Y CAGR: +18.9%

Operating Income

$52.1B +2005.1% ▲

Net Income

$52.6B +5895.6% ▲

EPS (Diluted)

$1368.38 +5870.2% ▲

EBITDA

$53.7B +2717.9% ▲

5Y CAGR: +77.2%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$3.9B	$5.1B	$5.0B	$34.0B	$99.8B
YoY Growth	-91.0%	+29.7%	-2.2%	+586.9%	+193.6%
Cost of Revenue	$3.3B	$3.5B	$2.0B	$2.2B	$3.3B
Gross Profit	$612M	$1.6B	$2.7B	$31.8B	$96.5B
Gross Margin	15.7%	31.0%	55.5%	93.5%	96.7%
R&D Expenses	$22.6B	$23.3B	$24.9B	$21.4B	$0
SG&A Expenses	$5.5B	$6.2B	$8.5B	$4.4B	$0
Operating Expenses	$28.2B	$29.6B	$33.4B	$34.5B	$44.3B
Operating Income	-$28.0B	-$28.5B	-$32.7B	-$2.7B	$52.1B
Operating Margin	-717.8%	-563.3%	-659.6%	-8.0%	52.2%
Interest Expense	$108M	$316M	$407M	$1.1B	$2.3B
Income Before Tax	-$28.6B	-$28.0B	-$32.3B	-$1.1B	$52.8B
Tax Expense	$7M	-$209M	-$3.8B	$472M	-$2.0B
Net Income	-$26.3B	-$24.4B	-$24.3B	$877M	$52.6B
Net Margin	-672.9%	-482.6%	-490.4%	2.6%	52.6%
EPS (Diluted)	$-827.37	$-763.19	$-634.86	$22.92	$1368.38
EBITDA	-$27.0B	-$26.0B	-$30.0B	$1.9B	$53.7B
Shares Outstanding	32M	32M	38M	38M	38M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$29.1B	$2.3B	$1.9B	$10.0B	$8.9B	$78.9B	$3.6B	$52.6B
Cost of Revenue	$669M	$612M	$359M	$470M	$557M	$560M	$826M	$779M
Gross Profit	$28.4B	$1.7B	$1.6B	$9.5B	$8.4B	$78.4B	$2.8B	$51.9B
Gross Margin	97.7%	73.8%	81.5%	95.3%	93.8%	99.3%	77.3%	98.5%
R&D Expenses	$4.2B	$8.4B	$5.5B	$6.9B	$5.3B	$9.9B	$6.4B	$9.0B
SG&A Expenses	$1.2B	$950M	$1.4B	$10.2B	$1.3B	$3.4B	$2.8B	$4.0B
Operating Expenses	$8.7B	$8.8B	$9.9B	$10.2B	$8.8B	$17.0B	$12.8B	$13.2B
Operating Income	$19.6B	-$7.0B	-$8.3B	-$632M	-$373M	$61.4B	-$10.0B	$38.7B
Operating Margin	67.6%	-301.2%	-429.8%	-6.3%	-4.2%	77.8%	-273.8%	73.5%
Interest Expense	$450M	$483M	$532M	$1.9B	$569M	$623M	$658M	$711M
Income Before Tax	$19.4B	-$6.5B	-$7.7B	-$2.4B	$704M	$62.3B	-$4.9B	$40.8B
Tax Expense	$105M	$371M	$24M	$78M	$56M	-$1.8B	$46M	$19M
Net Income	$16.9B	-$4.9B	-$5.9B	-$1.8B	-$489M	$60.8B	-$2.7B	$36.7B
Net Margin	58.2%	-208.1%	-306.8%	-18.4%	-5.5%	77.1%	-74.7%	69.6%
EPS (Diluted)	$442.00	$-127.13	$-155.35	$-48.17	$-13.00	$1590.00	$-71.23	$958.14
EBITDA	$20.3B	-$5.5B	-$6.7B	$9.9B	$1.7B	$61.4B	-$9.6B	$39.1B
Shares Outstanding	38M	38M	38M	38M	38M	38M	38M	38M

039200.KQ KOE